Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Fosbretabulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 known ✓ | Q9H4B7 | 14/20 | 0.60 |
| ▸ | TUBB4A known ✓ | P04350 | 8/20 | 0.60 |
| ▸ | TUBB known ✓ | P07437 | 8/20 | 0.60 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 8/20 | 0.60 |
| ▸ | TUBA1B known ✓ | P68363 | 8/20 | 0.60 |
| ▸ | TUBA4A known ✓ | P68366 | 8/20 | 0.60 |
| ▸ | TUBB4B known ✓ | P68371 | 8/20 | 0.60 |
| ▸ | TUBB3 known ✓ | Q13509 | 8/20 | 0.60 |
| ▸ | TUBB2A known ✓ | Q13885 | 8/20 | 0.60 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 8/20 | 0.60 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 8/20 | 0.60 |
| ▸ | TUBA1A known ✓ | Q71U36 | 8/20 | 0.60 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 8/20 | 0.60 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 8/20 | 0.60 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 8/20 | 0.60 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.60 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.60 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosbretabulin SCHEMBL9708418 | 1.00 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL66079 | 0.99 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL29417596 | 0.99 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL29374788 | 0.99 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL9707816 | 0.97 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL3542758 | 0.97 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14175312 | 0.96 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14114359 | 0.91 | TUBB1 (0.64) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13940886 | 0.90 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13813245 | 0.89 | TUBB1 (0.51) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659262-B2 | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di-amino acid salts, and mono- and di-amino acid ester salts | BRISTOL-MYERS SQUIBB CO. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659261-B2 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | BRISTOL-MYERS SQUIBB CO. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090186857-A1 | Combretastatin A-4 Phosphate Prodrug Mono- and Di- Organic Amine Salts, Mono- and Di- Amino Acid Salts, and Mono- and Di- Amino Acid Ester Salts | BRISTOL-MYERS SQUIBB COMPANY | 2009-07-23 | — | — | US | disclosed |
| US-7524832-B2 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts and mono-and di-amino acid ester salts | BRISTOL-MYERS SQUIBB CO. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070270617-A1 | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di-amino acid salts, and mono- and di-amino acid ester salts | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20060172980-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts and mono-and di-amino acid ester salts | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-03 | — | — | US | disclosed |
| US-20060165772-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060166942-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| EP-1559718-A1 | Combretastatin A-4 phosphate prodrug salts with nitrogen-containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050153939-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | US | disclosed |
| EP-1320534-B1 | COMBRETASTATIN A-4 PHOSPHATE PRODRUG SALTS WITH NITROGEN-CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6855702-B2 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040054212-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-6670344-B2 | Having greater solubility than native combretastatin A-4, and rapidly regenerate combretastatin A-4 under physiological conditions; for use in cancer therapy | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| EP-1320534-A1 | COMBRETASTATIN A-4 PHOSPHATE PRODRUG SALTS WITH NITROGEN-CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20020072507-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono--and di-amino acid salts, and mono-and di-amino acid ester salts | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| WO-2002022626-A1 | COMBRETASTATIN A-4 PHOSPHATE PRODRUG SALTS WITH NITROGEN-CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-1992016486-A1 | SUBSTITUTED DIPHENYLETHYLENES AND ANALOGUES OR DERIVATIVES THEREOF | ASTON MOLECULES LIMITED (GB) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153939-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | SLC7A1, CAD, GART | TUBB1 2278/4885TUBB4A 385/4885TUBB 1601/4885 |
| US-20060172980-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts and mono-and di-amino acid ester salts | SLC7A1, CAD, GART | TUBB1 2315/4885TUBB4A 379/4885TUBB 1649/4885 |
| US-20040054212-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | SLC7A1, CAD, GART | TUBB1 2278/4885TUBB4A 385/4885TUBB 1601/4885 |
| US-20060165772-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | SLC7A1, CAD, GART | TUBB1 2278/4885TUBB4A 385/4885TUBB 1601/4885 |
| US-20070270617-A1 | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di-amino acid salts, and mono- and di-amino acid ester salts | SLC7A1, CAD, GART | TUBB1 2278/4885TUBB4A 385/4885TUBB 1601/4885 |
| US-20060166942-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts | SLC7A1, CAD, GART | TUBB1 2278/4885TUBB4A 385/4885TUBB 1601/4885 |
| US-20090186857-A1 | Combretastatin A-4 Phosphate Prodrug Mono- and Di- Organic Amine Salts, Mono- and Di- Amino Acid Salts, and Mono- and Di- Amino Acid Ester Salts | SLC7A1, CAD, GART | TUBB1 2278/4885TUBB4A 385/4885TUBB 1601/4885 |
| US-20020072507-A1 | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono--and di-amino acid salts, and mono-and di-amino acid ester salts | SLC7A1, CAD, GART | TUBB1 2430/4885TUBB4A 428/4885TUBB 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.